JP2022517865A5 - - Google Patents
Info
- Publication number
- JP2022517865A5 JP2022517865A5 JP2021543528A JP2021543528A JP2022517865A5 JP 2022517865 A5 JP2022517865 A5 JP 2022517865A5 JP 2021543528 A JP2021543528 A JP 2021543528A JP 2021543528 A JP2021543528 A JP 2021543528A JP 2022517865 A5 JP2022517865 A5 JP 2022517865A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797573P | 2019-01-28 | 2019-01-28 | |
| US62/797,573 | 2019-01-28 | ||
| PCT/US2020/015457 WO2020160022A1 (en) | 2019-01-28 | 2020-01-28 | Compositions and methods for treatment of diseases involving cxcl1 function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022517865A JP2022517865A (ja) | 2022-03-10 |
| JP2022517865A5 true JP2022517865A5 (enExample) | 2023-02-03 |
Family
ID=71841416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543528A Pending JP2022517865A (ja) | 2019-01-28 | 2020-01-28 | Ｃｘｃｌ１機能に関与する疾患の治療のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11292832B2 (enExample) |
| EP (1) | EP3917949A4 (enExample) |
| JP (1) | JP2022517865A (enExample) |
| CN (1) | CN113544143A (enExample) |
| CA (1) | CA3127943A1 (enExample) |
| WO (1) | WO2020160022A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4471057A4 (en) * | 2022-01-27 | 2026-03-04 | Chiome Bioscience Inc | ANTI-CXCL1 HUMAN ANTIBODY |
| WO2026060413A1 (en) * | 2024-09-16 | 2026-03-19 | Calgent Biotechnology Co., Ltd. | Single chain antibodies and use thereof |
| CN120795145A (zh) * | 2025-07-22 | 2025-10-17 | 青岛大学 | 一种抗cxcl1的纳米抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5078015B2 (ja) * | 2005-09-02 | 2012-11-21 | 東レ株式会社 | 尿路上皮ガンの検出用キットおよび方法 |
| US7858752B2 (en) * | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| CN101261275A (zh) * | 2008-01-23 | 2008-09-10 | 李力 | 一种用于早期卵巢癌诊断的检测试剂盒 |
| CN102203177A (zh) | 2008-10-29 | 2011-09-28 | 日本瑞翁株式会社 | 腈共聚物胶乳组合物和腈共聚物橡胶组合物 |
| CN102245767B (zh) * | 2008-10-31 | 2013-09-18 | 东丽株式会社 | 人cxcl1蛋白质的免疫学测定方法 |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| WO2014113804A1 (en) * | 2013-01-21 | 2014-07-24 | Abbvie Inc. | Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease |
| US9290570B2 (en) | 2013-03-15 | 2016-03-22 | Eli Lilly And Company | Pan-ELR+ CXC Chemokine Antibodies |
| WO2014184384A1 (en) * | 2013-05-17 | 2014-11-20 | Centre National De La Recherche Scientifique (Cnrs) | Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications |
| US11267881B2 (en) * | 2017-09-14 | 2022-03-08 | Charles ROSSER | Compositions and methods for treatment of diseases involving CXCL1 function |
| US11603569B2 (en) * | 2018-03-20 | 2023-03-14 | Cedars-Sinai Medical Center | Immune modulating genes for prognosis, diagnosis and treatment of metastatic disease, and drug identification methods thereof |
-
2020
- 2020-01-28 CA CA3127943A patent/CA3127943A1/en active Pending
- 2020-01-28 EP EP20747679.7A patent/EP3917949A4/en active Pending
- 2020-01-28 US US16/982,456 patent/US11292832B2/en active Active
- 2020-01-28 WO PCT/US2020/015457 patent/WO2020160022A1/en not_active Ceased
- 2020-01-28 CN CN202080017507.1A patent/CN113544143A/zh active Pending
- 2020-01-28 JP JP2021543528A patent/JP2022517865A/ja active Pending
-
2022
- 2022-03-07 US US17/688,740 patent/US11760796B2/en active Active
-
2023
- 2023-08-18 US US18/451,872 patent/US20240018229A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038003A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP2025016349A5 (enExample) | ||
| JP2009539348A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| JP2022519118A5 (enExample) | ||
| CN113354729A (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| JP2020514277A5 (enExample) | ||
| JP2023093753A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2023520969A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2023071956A5 (enExample) | ||
| RU2009111884A (ru) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования | |
| JP2012525829A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| CN113354730B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| JP2021530244A5 (enExample) | ||
| JP2011527899A5 (enExample) | ||
| JP2011526249A5 (enExample) | ||
| JP2024024114A5 (enExample) | ||
| WO2021129891A1 (zh) | 可结合cd4的多肽及其应用 | |
| JP2020513759A5 (enExample) | ||
| JP2024516098A5 (enExample) | ||
| CN111093702A (zh) | 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗 |